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Abstract
Introduction: The aim of this study was to assess the validity of a continuous Metabolic Syndrome score (cMetS) in a nationally repre-
sentative sample of Iranian children and to identify sex and age-specific optimal cut-off points of cMetS that are associated with MetS.
Material and methods: This study was conducted among 3,254 schoolchildren aged 10–18 years. cMetS was derived by aggregating age 
and sex-standardised residuals of waist circumference (WC), mean arterial pressure (MAP), glucose, high density lipoprotein-cholesterol 
(HDL-C) and triglycerides (TG). To determine the optimal cut-off points of cMetS for predicting MetS, receiver operator characteristic 
(ROC) curve analysis was used with an estimation of the variables’ sensitivity and specificity.
Results: A graded relationship was documented between cMetS and the number of risk factors. Increasing mean values of cMetS with increasing 
numbers of components were apparent for both genders. The overall optimal cMetS cut-off point for predicting the presence of MetS was 2.93 [sen-
sitivity = 92%, specificity = 91%, area of the curve = 0.96 (0.95–0.97)]. The values for boys and girls were 2.97 and 3.26 respectively in the total study.
Conclusion: This nationwide study confirmed the validity of the cMetS score in a population-based sample of Iranian children. cMetS 
appears to be an appropriate index for investigating the association between potential risk factors and MetS in epidemiological research 
in Iran. (Endokrynol Pol 2013; 64 (4): 278–284)
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Streszczenie
Wstęp: Celem pracy była ocena trafności ciągłego wskaźnika zespołu metabolicznego (cMetS) na próbie reprezentatywnej irańskich dzieci 
oraz zidentyfikowanie zależnych od płci i wieku optymalnych wartości odcięcia wskaźnika cMetS związanych z zespołem metabolicznym.
Materiał i metody: Badanie zostało przeprowadzone z udziałem 3254 uczniów w wieku od 10 do 18 lat. cMetS był ustalany poprzez 
zagregowanie residuów standaryzowanych względem wieku i płci następujących parametrów: obwodu w pasie (WC, waist circumfe-
rence), średniego ciśnienia tętniczego (MAP, mean arterial pressure), stężenia glukozy, stężenia cholesterolu frakcji lipoprotein wysokiej 
gęstości (HDL-C, high density lipoprotein cholesterol) oraz stężenia triglicerydów (TG). W celu ustalenia optymalnych punktów odcięcia 
dla przewidywania obecności zespołu metabolicznego na podstawie cMetS zastosowano analizę krzywej ROC (receiver operating 
characteristic) z oszacowaniem czułości i swoistości zmiennych.
Wyniki: Wykazano stopniowany związek między wskaźnikiem cMetS a liczbą czynników ryzyka. W przypadku obu płci zaobserwowano 
wyraźny wzrost średnich wartości wskaźnika cMetS wraz ze wzrostem liczby komponentów. Ogólna optymalna wartość odcięcia wskaź-
nika cMetS dla przewidywania obecności zespołu metabolicznego wyniosła 2,93 [czułość = 92%, swoistość = 91%, pole powierzchni pod 
krzywą = 0,96 (0,95–0,97)]. Wartość dla chłopców wyniosła w badaniu 2,97, a dla dziewcząt — 3,26.
Wniosek: W przeprowadzonym badaniu ogólnokrajowym potwierdzono trafność wskaźnika cMetS w populacji irańskich dzieci. Wskaźnik 
cMetS wydaje się odpowiednim wskaźnikiem do zastosowania w badaniach epidemiologicznych nad związkiem pomiędzy potencjalnymi 
czynnikami ryzyka a występowaniem zespołu metabolicznego w Iranie. (Endokrynol Pol 2013; 64 (4): 278–284)
Słowa kluczowe: ciągły wskaźnik zespołu metabolicznego, trafność, dzieci
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Introduction
Metabolic Syndrome (MetS) is characterised by a cluster 
of risk factors that confers an increased risk for cardio-
vascular disease mortality and morbidity better than 
any of its individual components [1]. The prevalence 
of MetS is rising in the adult population worldwide 
[2]. A growing body of evidence has demonstrated 
that exposure to obesity in early life significantly con-
tributes to the development of MetS during childhood 
and adolescence [3]. The lack of a universal definition 
of MetS in the paediatric age group may be the cause 
of controversial findings across epidemiologic studies 
and the low prevalence of MetS in some populations 
[4, 5]. Because of the low prevalence rate, the American 
Diabetes Association and the European Association 
for the Study of Diabetes have recommended using 
a continuous value of MetS (cMetS) risk score for asso-
ciation studies between MetS and potential risk factors 
in children and adolescents [6].
Several studies have supported using a cMetS risk 
score instead of binary definition in epidemiologic 
studies [7, 8]. Such a definition is proposed to have the 
following advantages: a) cardiovascular and diabetes 
risk is a progressive function and increases progres-
sively as the number of MetS components increases, it 
also eliminates the need to dichotomise these compo-
nents; b) statistical power decreases with dichotomising 
continuous outcome variables; and c) compared to the 
dichotomous approach, cMetS risk score is more sensi-
tive and less error-prone [9–11]. Previous methods used 
to derive the cMetS score include principal components 
[12], Z scores [13–15], and percentile rankings [16]. Few 
studies have examined the construct validity of cMetS 
value and its association with MetS in children and 
adolescents [17, 18].
Middle East populations are suggested to bear the 
highest worldwide burden of diabetes up to 2020 [19]. 
Similar to most low- and middle-income countries, 
Iran is facing an epidemiological shift, most notably in 
terms of nutrition transition [20]. Thus, it is important 
to determine a valid score for the definition of paedi-
atric MetS, and to identify at-risk individuals to help 
the primary prevention of underlying factors of MetS.
We aimed to determine the validity of cMetS, and 
to identify the age- and gender-specific optimal cut-off 
points of cMetS in a nationally representative sample 
of the paediatric population.
Material and methods
Participants and study design 
The data used in this study was collected as part of the 
‘National Survey of School Student High Risk Behav-
iours’(2009–2010) as the third survey of the school-based 
surveillance system entitled ‘Childhood and Ado-
lescence Surveillance and Prevention of Adult Non-
communicable Disease’ (CASPIAN) study. We have 
previously described the methods of this study in detail 
[21]. The study was approved by the ethics committee 
and other relevant national regulatory organisations.
The present study was performed among 3,254 pu-
pils aged 10-18 years who were selected via multistage 
random cluster sampling method from urban and rural 
areas of 27 provinces in Iran. Eligible schools for our 
study were stratified according to the information bank 
of the Ministry of Health and Medical Education and 
then they were selected randomly. In selected schools, 
the pupils were also selected randomly. Sampling and 
examinations were begun after complete explanation 
of the study’s objectives and protocols for pupils and 
their parents, obtaining written informed consent from 
parents and oral assent from the pupils. A team of 
trained health care professionals recorded information 
in a checklist and carried out the examinations under 
the standard protocol using calibrated instruments.
Clinical and laboratory measurements
Height (Ht) and weight (Wt) were measured without 
shoes and with light clothing, and body mass index 
(BMI = weight [kg]⁄height [m2]) was calculated. 
Waist circumference (WC) was measured midway 
between the lower border of the rib margin and the 
iliac crest at the end of normal expiration. WC and 
height were measured using a non-elastic tape. Two 
measurements of systolic blood pressure (SBP) and 
diastolic blood pressure (DBP) were performed using 
a standardised mercury sphygmomanometer on the 
right arm after a 15-minute rest in a sitting position; 
the first and fifth Korotkoff sounds were recorded as 
systolic and diastolic BP, respectively. The mean of 
the two measurements was considered as the sub-
ject’s blood pressure. Mean arterial pressure (MAP) 
was calculated using the following formula: MAP = 
= [(SBP–DBP)/3] + DBP.
A blood sample was drawn between 7 am and 9 am 
from all the study participants after 12 to 14 hours of 
overnight fasting and delivered to the laboratory on the 
same day. Fasting blood glucose (FBG), total cholesterol 
(TC), high density lipoprotein-cholesterol (HDL-C) and 
triglycerides (TG) were measured enzymatically by 
auto-analysers. HDL-C was determined after dextran 
sulphate-magnesium chloride precipitation of non-
HDL-C [22]. Considering that collecting high quality 
data was critical to the success of our multi-centre pro-
ject, the Data and Safety Monitoring Board (DSMB) of 
the project was taken in account the different levels of 
quality assurance and control. 
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Definition of terms
Metabolic Syndrome (MetS)
Since no universally accepted definition exists for MetS 
in children and adolescents, as in the first survey of the 
CASPIAN study [5] we used the definition provided 
by Cook et al. [23]. This definition is based on criteria 
analogous to those of the National Cholesterol Educa-
tion Programme Expert Panel on Detection, Evaluation, 
and Treatment of High Blood Cholesterol in Adults 
Adult Treatment Panel III (ATP III) [24]. It defines MetS 
as having at least three of the following criteria: WC at 
or above the 90th percentile value for age and sex; SBP 
and DBP at or above the 90th percentile for age, sex and 
height; the midpoint value for HDL-C (≤ 40 mg/dL) was 
used as a 10th percentile value; the midpoint value for 
TG (≥ 110 mg/dL) was taken as the 90th percentile value 
for age. FBG levels of ≥ 100 mg/dL were considered to 
be high [25].
Calculation of cMetS score
The cMetS score was derived by first standardising 
the residuals for WC, MAP, HDL-C, TG, and FBG by 
regressing them on age and sex to account for age- and 
gender-related differences [8]. Because the standard-
ised HDL-C is inversely related to the MetS risk, it was 
multiplied by — 1. The cMetS score was calculated as 
the sum of the standardised residuals (z scores) for the 
individual variables. These factors were the same vari-
ables used in adult clinical criteria for MetS [26]. MAP 
was used since including both SBP and DBP would load 
two BP variables in its calculation. A higher cMetS score 
indicates a less favourable metabolic profile.
Statistical analysis
Findings on continuous variables were expressed as 
means ± standard deviation (SD) and categorical data 
was expressed as a percentage. The Student two-tailed 
t test was applied to compare the mean differences of 
the variables between both gender and age.
To determine the optimal cut-off point of cMetS for 
predicting MetS, receiver operator characteristic (ROC) 
curve analysis was used with an estimation of the vari-
able’s sensitivity and specificity. The cut-off point for 
each variable was assessed by the minimum value of ‏ 
[27] which represents the maximum sum of sensitivity 
and specificity (MAXss) in each gender stratified by age.
The area under curve (AUC) relates to the overall 
ability of using the cMetS cut-off point to discriminate 
between those with and without MetS. In this analysis, 
AUC can be considered to be equal to the probability 
that a randomly drawn individual from a sample of 
subjects with MetS has a higher cMetS than a person 
randomly drawn from the non-MetS sample. AUC can 
be interpreted according to the following principles: test 
equal to chance (AUC = 0.5), less accurate (0.5 < AUC 
≤ 0.7), moderately accurate (0.7 < AUC ≤ 0.9), highly 
accurate (0.9 < AUC ≤ 1.0), and perfect performance 
tests (AUC = 1.0) [28].
SPSS software package (version 16; SPSS Inc., 
Chicago, IL, USA) was used for data analyses and a p 
value of < 0.05 was considered to indicate statistical 
significance.
Results
The participants in this multicentre study included 1,679 
boys and 1,575 girls aged 10-18 years. The anthropomet-
ric and metabolic characteristics of the individuals who 
were eligible for this study are stratified by age and are 
shown in Table I. Girls had an average higher WC, SBP, 
DBP and FBG than boys; however, the mean values of 
BMI, TG and TC were higher in boys than in girls. Other 
than HDL and TC, in both genders, the BMI, WC, SBP, 
DBP, and TG was raised significantly by increasing the 
age. There was no significant difference in mean FBG 
between age groups.
Overall, 423 (8.1%) of our subjects were overweight 
and 477 (9.2%) were obese. In the age group 10–13.9 
years, 9.5% (n = 94) and 11.2% (n = 110) of boys were 
overweight and obese, respectively. In the 14–18 years 
boy category, 155 (9.6%) and 166 (10.3%) of participants 
were overweight and obese, respectively. In girls, 61 
(6.3%) and 80 (8.3%) in the age group 10–13.9 years were 
placed in overweight and obese groups, respectively. 
The percentages of overweight and obese subjects in 
the age group 14–18 years were 6.9% (n = 113) and 7.4% 
(n = 121), respectively.
Table II shows the mean values of cMetS in 
participants according to the number of MetS com-
ponents. In total, 43.9% of the participants did not 
have any MetS components, whereas 4.4% had MetS. 
A graded relationship was documented between 
cMetS and the number of risk factors. Increasing the 
mean values of cMetS with increasing the numbers 
of components was apparent for both genders and 
in both age groups. 
Table III presents the cut-off points of cMetS to 
predict the presence of MetS with their correspond-
ing specificity and sensitivity by gender. In boys, 
cMetS values that maximised the sensitivity and 
specificity for MetS ranged from 2.34 in 10–13.9 
years to 2.97 in 14–18 years. The analogous values 
for girls ranged from 3.26 in 10–13.9 years to 2.47 in 
14–18 years. The overall optimal cMetS cut-off point 
of MetS was 2.93 [sensitivity = 92%, specificity = 
91%, area of the curve = 0.96 (0.95–0.97)] (Fig. 1). As 
a whole, the values for boys and girls were 2.97 and 
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Table I. Characteristics of participants according to gender and age groups
Tabela I. Charakterystyka uczestników badania w zależności od płci i grupy wiekowej 
Age groups (years)
10–13.9 14–18 Total
Boys
n 638 1,041 1,679
Age (years) 11.98 ± 0.89 16.04 ± 1.41 14.49 ± 2.33b
BMI [kg/m2] 17.59 ± 3.69 20.71 ± 3.90 19.53 ± 4.11b
WC [cm] 61.87 ± 8.69 69.82 ± 9.40 66.84 ± 9.92b
SBP [mm Hg] 97.08 ± 13.64 103.88 ± 12.53 101.25 ± 13.39b
DBP [mm Hg] 62.55 ± 10.93 66.06 ± 10.05 64.73 ± 10.53b
FBG [mg/dL] 86.65 ± 11.78 87.48 ± 16.41 87.10 ± 14.83
TG [mg/dL] 92.10 ± 41.67 95.65 ± 40.55 94.32 ± 41.0b
TC [mg/dL] 150.02 ± 31.11 151.19 ± 31.65 150.75 ± 31.44
HDL-C 47.29 ± 14.28 45.29 ± 14.02 46.22 ± 14.14b
Girls
n 572 1,003 1,575
Age (years) 12.12 ± 0.82 16.04 ± 1.40 14.60 ± 2.25b
BMI [kg/m2] 17.59 ± 3.63 20.05 ± 4.05 19.14 ± 4.10b
WC [cm] 63.86 ± 10.16 72.40 ± 11.08 69.26 ± 11.51b
SBP [mm Hg] 100.97 ± 13.08 106.86 ± 13.95 104.71 ± 13.93b
DBP [mm Hg] 64.83 ± 11.11 67.92 ± 11.01 66.77 ± 11.14b
FBG [mg/dL] 80.23 ± 12.74 88.38 ± 12.63 88.33 ± 12.67
TG [mg/dL] 86.46 ± 39.77 93.73 ± 45.76 91.06 ± 43.79b
TC [mg/dL] 154.84 ± 31.39 140.86 ± 30.37 146.03 ± 31.48b
HDL-C 48.52 ± 15.58 44.61 ± 12.94 46.05 ± 14.09b
Total
n 1,210 2,044 3,254
Age (years) 12.05 ± 0.86a 16.04 ± 1.40 14.55 ± 2.29b
BMI [kg/m2] 17.59 ± 3.66 20.38 ± 4.00a 19.33 ± 4.10a, b
WC [cm] 62.85 ± 9.49a 71.12 ± 10.36a 68.05 ± 10.81a, b
SBP [mm Hg] 98.95 ± 13.51a 105.38 ± 13.35a 102.96 ± 13.76a, b
DBP [mm Hg] 63.67 ± 11.08a 66.98 ± 10.57a 65.74 ± 10.88a, b
FBG [mg/dL] 87.42 ± 12.27a 87.92 ± 14.67 87.74 ± 13.83a
TG [mg/dL] 89.29 ± 40.02a 94.70 ± 43.21 92.71 ± 42.42a, b
TC [mg/dL] 152.37 ± 31.32a 146.07 ± 31.44a 148.42 ± 31.55a, b
HDL-C 47.89 ± 14.93 45.10 ± 13.50 46.14 ± 14.11b
ap < 0.05 between genders, bp < 0.05 between age groups; BMI — body mass index; WC — waist circumference; SBP — systolic blood pressure; DBP — diastolic 
blood pressure; FBG — fasting blood glucose; TG v triglyceride; TC — total cholesterol; HDL-C — high density lipoprotein cholesterol
3.26, respectively. The overall performance of the 
ROC curves for the estimated cMetS cut-off points 
were quantified by computing sex- and age-specific 
AUCs. In all groups, cMetS performed well (0.9 < 
AUC ≤ 1.0; highly accurate) in classifying subjects to 
true MetS status (Fig. 2). 
Discussion
This study confirmed the utility and validity of the 
cMetS score in a nationally representative sample of 
Iranian children and adolescents. cMetS appears to be 
an appropriate index for investigating the association 
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Figure 1. Overall ROC curve of cMetS risk score corresponding 
to Metabolic Syndrome. ROC — receiver operating characteristics; 
cMetS — continuous Metabolic Syndrome
Rycina 1. Ogólna krzywa ROC dla wartości wskaźnika cMetS 
odpowiadających zespołowi metabolicznemu
Table III. Receiver operator curve for cMetS score for identifying children with MetS
Tabela III. Krzywa ROC dla wskaźnika cMetS w celu identyfikacji dzieci z zespołem metabolicznym
Sex/Age value cMetS score cut-off points Sensitivity (%) Specificity (%) AUC (95% CI)
Boys
 10–13.9 2.34 94.0 (91.9–95.7) 87.0 (84.1–89.5) 0.96 (0.93–0.99)
 14–18 2.97 94.0 (92.3–95.3) 91.0 (89.0–92.6) 0.94 (0.91–0.98)
Girls
 10–13.9 3.26 100.0 (99.3–100) 93.0 (90.5–94.9) 0.98 (0.97–0.99)
 14–18 2.47 94.0 (92.2–95.3) 88.0 (85.9v89.9) 0.97 (0.96–0.98)
Sex-specific value
Boys 2.97 92.0 (90.6–93.3) 91.0 (89.5–92.3) 0.95 (0.92–0.97)
Girls 3.26 90.0 (88.4–91.4) 93.0 (91.6–94.2) 0.97 (0.96–0.98)
Overall value 2.93 92.0 (91.0–92.9) 91.0 (89.9–91.9) 0.96 (0.95–0.97)
cMetS — continuous Metabolic Syndrome; AUC — area under curve
Table II. Continuous Metabolic Syndrome score by numbers of MetS components
Tabela II. Ciągły wskaźnik zespołu metabolicznego w zależności od liczby komponentów
MetS 
components
Boys Girls
10–13.9 years 14–18 years 10–13.9 years 14–18 years
N (%) cMetS 
score
N (%) cMetS 
score
N (%) cMetS 
score
N (%) cMetS
score
0 333 (52.2) –1.17 ± 1.83 475 (45.6) –1.45 ± 1.81 258 (45.1) –1.60 ± 1.72 363 (36.2) –1.89 ± 1.85
1 218 (34.2) 0.44 ± 1.78 383 (36.8) 0.32 ± 2.20 237 (41.4) 0.07 ± 1.89 429 (42.8) –0.02 ± 1.75
2 71 (11.1) 3.06 ± 2.05 148 (14.2) 2.44 ± 1.98 64 (11.2) 3.09 ± 2.18 143 (14.2) 2.56 ± 2.20
+3 16 (2.5) 5.47 ± 2.59 35 (3.4) 4.72 ± 2.12 13 (2.3) 6.35 ± 2.29 68 (6.8) 5.47 ± 2.30
Total 638 0.02 ± 2.45 1,041 -0.04 ± 2.56 572 –0.20 ± 2.56 1,003 0.04 ± 2.80
Values are mean (SD) and % where indicated; cMetS — continuous Metabolic Syndrome
Figure 2. Sex-specific ROC curves of cMetS risk score 
corresponding to Metabolic Syndrome. ROC — receiver operating 
characteristics; cMetS — continuous Metabolic Syndrome
Rycina 2. Osobne dla obu płci krzywe ROC dla wartości 
wskaźnika cMetS odpowiadających zespołowi metabolicznemu
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between potential risk factors and MetS in paediatric 
epidemiological research in our country.
MetS increases the risk of developing most chronic 
diseases, notably type 2 diabetes and cardiovascular 
diseases [29]. However, MetS is not limited to adults. 
There is a growing body of evidence about its pres-
ence from early childhood [30]. Changes in childhood 
lifestyle represent a significant concern in public 
health and paediatric medicine at both population 
and individual levels [31]. The prevalence of MetS 
in children and adolescents varies according to the 
definitions used for the components [32]. It must be 
emphasised that the lack of consensus in the defini-
tion may be responsible for varied findings across 
the epidemiologic studies [4]. Several studies have 
supported the use of continuous variables in a mul-
tivariate score system [11, 33]. cMetS is statistically 
more sensitive and less error-prone compared to 
the categorical approach. A study has demonstrated 
higher cMetS in Mexican-American children com-
pared to white boys and girls [34]. 
To the best of our knowledge, this study is the first 
investigation that uses a nationally representative 
sample to validate the cMetS score in children in the 
Middle East and North Africa (MENA) region. Our 
findings documented a graded relationship between 
cMetS and the number of MetS components, i.e. hav-
ing at least three MetS components is associated with 
the highest cMetS value. A rising mean value of cMetS 
with increasing the number of MetS components was 
observed in each age stratified gender. Furthermore, 
the overall optimal cMetS cut-off point which confers 
the risk of MetS was 2.93. A recent study by Okosun 
et al. [17] indicated that cMetS was a valid construct of 
MetS in children with a cut-off value of 1.94. Likewise, 
Eisenmann et al. found that a cMetS of 3.72 considered 
as the optimal cut-off point confers an increased risk of 
MetS in a sample of 7-9 year-old children [18]. Since the 
MetS score is a sample specific, the mean MetS score 
derived in one survey cannot be compared to other 
studies unless variables and distribution of data are 
similar in the samples [33].
Although in our study, the results of the ROC analy-
sis indicated different cut-off points of cMetS according 
to age and gender, cMetS was found to perform better 
in identifying MetS in both genders. In a previous na-
tional study, we showed that the prevalence of MetS in 
women was significantly higher than in men [35]. We 
suggest that the higher cut-off value of cMetS in women 
in our study compared to Western countries could be 
because of the underlying ethnic predispositions that 
contribute to insulin resistance and adverse body fat 
pattern in non-European populations [36]. Our findings 
highlighted an overall greater WC in girls than in boys. 
Considering the high prevalence of abdominal obesity 
in Iranian females [37], the higher relative risk for inci-
dent MetS in this group could be justified. Furthermore, 
in all age groups we found a significant increase in mean 
TG values in boys. Consistent with several studies [17, 
38], our findings suggest that central obesity and high 
TG have the most influence on MetS and cMetS score. 
Unhealthy diets, as well as the physical inactivity of 
Iranian children [39], could well be among the major 
contributors to the present and future health status of 
this group and are likely to confer an increased risk of 
chronic disease in adulthood [40]. These findings also 
confirm that the same set of adult criteria can be used 
in the calculation of the cMetS score and also highlights 
the importance of cMetS as a predictive utility on dis-
ease outcome [33, 41].
The validity of cMetS score in children has been 
examined in a few previous studies [17, 18, 42]. In our 
study, the construct validity of cMetS for MetS was high 
(AUC ≥ 0.94; sensitivity ≥ 90% and specificity ≥ 87%). In 
a study in children and adolescents 12-19 years old, the 
cMetS, determined by principal components analysis, 
was significantly higher in those individuals with MetS 
as defined by the NHANES [17]. Our findings are con-
sistent with this study and support the use of cMetS in 
epidemiological surveys.
Our findings should be interpreted while consider-
ing some limitations. The major limitation of this study 
and previous studies about cMetS is the specificity of 
sample. Therefore, a standardised method of calculating 
the score may prove beneficial in comparing studies. 
Another limitation is that we included WC, MAP, HDL-
C, TG, and FBG in calculation of cMetS. Some studies 
have used the markers of insulin resistance, instead of 
serum glucose levels, because blood glucose is usually 
in the normal range in youth [43]. We selected blood 
glucose levels because they were employed by ATP-III, 
and International Diabetes Federation adult clinical 
criteria for the definition of MetS [24, 26]. The other 
limitation was that we could not stratify according to 
maturation stage because of the limitations for the large 
number of study participants.
For the first time in Iran, and to the best of our 
knowledge in the Middle East and North Africa 
(MENA), we have assessed the construct and predic-
tive validity of cMetS in a large nationally representa-
tive sample of children in order to find early identi-
fication of those who are at risk. This is also the first 
investigation to determine the age- and sex-specific 
cMetS cut-off points in Iranian children and adoles-
cents. We noticed to age groups because of the strong 
association of age with maturity and the influence of 
growth and maturation on the development of the 
metabolic risk factors.
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Conclusion
This study shows that cMetS is an appropriate and valid 
index of MetS for paediatric epidemiological surveys. The 
use of cMetS enhances the role of potential risk factors in 
MetS. Further studies are needed to compare the ultimate 
net value of cMetS with the dichotomised definition of 
MetS. We also need a standardised and practical method 
of calculating the score to compare different populations, 
and then cMetS score could be used in clinical practice and 
public health to better understand the prevention and 
treatment of this emerging paediatric condition.
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